Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress

Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued…

Lilly Q2 revenue $23B (+48%) led by Mounjaro/Zepbound GLP-1; non-GAAP EPS +33% ($8.38); FY guidance raised to $85-87B. Retatrutide obesity program completes Phase 3 (BLA Q1 2027); four acquisitions (Orna, Ajax, Centessa, Kelonia) plus $4.5B capex intensify growth pipeline.